T1	Intervention 76 112	patients with chronic kidney disease
T2	Intervention 463 606	48-hour and 30-day outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT)
